Trial · NCT03486912
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 | BMS-986036 10 mg | 28.2 | Percentage of Participants | ||
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 | BMS-986036 20 mg | 24.3 | Percentage of Participants | ||
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 | BMS-986036 40 mg | 28.2 | Percentage of Participants | ||
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 | Placebo | 30.8 | Percentage of Participants | ||
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 48 | BMS-986036 10 mg | 38.5 | Percentage of Participants | ||
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 48 | BMS-986036 20 mg | 32.4 | Percentage of Participants | ||
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 48 | BMS-986036 40 mg | 33.3 | Percentage of Participants | ||
| The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Ishak Fibrosis Score at Week 48 | Placebo | 35.9 | Percentage of Participants | ||
| The Percentage of Participants With Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) or NASH Improvement at Week 48 | BMS-986036 10 mg | 33.3 | Percentage of Participants | ||
| The Percentage of Participants With Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) or NASH Improvement at Week 48 | BMS-986036 20 mg | 40.5 | Percentage of Participants | ||
| The Percentage of Participants With Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) or NASH Improvement at Week 48 | BMS-986036 40 mg | 35.9 | Percentage of Participants | ||
| The Percentage of Participants With Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) or NASH Improvement at Week 48 | Placebo | 30.8 | Percentage of Participants | ||
| The Percentage of Participants Who Achieved >=1 Point Improvement in Fibrosis at Week 48 | BMS-986036 10 mg | 35.9 | Percentage of Participants | ||
| The Percentage of Participants Who Achieved >=1 Point Improvement in Fibrosis at Week 48 | BMS-986036 20 mg | 29.7 | Percentage of Participants | ||
| The Percentage of Participants Who Achieved >=1 Point Improvement in Fibrosis at Week 48 | BMS-986036 40 mg | 28.2 | Percentage of Participants | ||
| The Percentage of Participants Who Achieved >=1 Point Improvement in Fibrosis at Week 48 | Placebo | 33.3 | Percentage of Participants | ||
| The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 48 | BMS-986036 10 mg | 61.8 | Percentage of Participants | ||
| The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 48 | BMS-986036 20 mg | 54.2 | Percentage of Participants | ||
| The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 48 | BMS-986036 40 mg | 41.9 | Percentage of Participants | ||
| The Percentage of Participants With Any Improvement in Collagen Proportionate Area (CPA) at Week 48 | Placebo | 53.1 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03486912/results